Lilly’s migraine treatment approval adds to Teva worries, says Wells Fargo

Wells Fargo analyst David Maris noted that Eli Lilly (LLY) received FDA approval of Emgality for the prevention of migraines and announced a U.S. list price of $6,900 annually, which is in line with Teva’s (TEVA) Ajovy and Aimovig from Amgen (AMGN) and Novartis (NVS). Lilly’s approval adds to Teva investor worries, said Maris, who sees migraines being a competitive market with similar drugs “where the competitors are marketing powerhouses…and Teva is undergoing a lot of organizational change.” He maintains a Market Perform rating on Teva shares.
https://thefly.com/landingPageNews.php?id=2797043